SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant market volatility after a Blue Origin rocket launch failed to place the BlueBird 7 satellite into its intended orbit, forcing the company to de-orbit the unit. While the community is actively debating the reliability of Blue Origin versus SpaceX and worrying about potential delays to the company's 2026 launch cadence, many investors remain bullish on the long-term thesis, noting that the loss is covered by insurance and production for subsequent satellites remains ongoing.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as traders closely monitor escalating geopolitical tensions in the Middle East alongside conflicting headlines regarding potential peace talks. Market participants are actively debating whether this volatility signals an impending pullback from recent highs or if algorithmic buying and tech earnings momentum will continue to drive a melt-up.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating significant market buzz as traders anticipate the signing of a federal executive order focused on fast-tracking ibogaine research for PTSD and addiction treatment. The community is actively debating the stock's potential for a short squeeze, driven by a tight float and the belief that the company's GMP-compliant supply chain positions it as a key beneficiary of new policy tailwinds.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is gaining strong investor attention as the community anticipates potential breakthroughs in its REGAL Phase 3 trial for GPS and upcoming data on SLS009. Discussions are dominated by speculation regarding an imminent readout of survival events, a potential short squeeze fueled by significant institutional interest, and growing confidence in the company's oncology platform.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is rallying sharply after receiving government approval to increase its ownership stake in the Tanbreez rare earth project to 92.5%, a major milestone that strengthens its control over a key strategic asset. The community is buzzing with bullish sentiment and active debate, with many investors pointing to the de-risking of the project and its geopolitical importance as catalysts for a potential short squeeze.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is currently trending as the community debates its long-term potential versus short-term volatility, with strong enthusiasm fueled by recent global expansion efforts in Japan and Saudi Arabia. Investors are actively discussing the company's immunotherapy platform, its path toward potential label expansions for Anktiva, and the ongoing struggle against regulatory hurdles while tracking institutional movements.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is seeing significant market activity as investors monitor incoming FDA National Priority Vouchers and a recent executive order aimed at accelerating psychedelic research. While the community is actively debating the stock's potential for growth, breakthrough clinical milestones, and M&A prospects, discussions also center on historical management concerns and dilution risks associated with the company's past operations.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors react to a high-profile White House executive order aimed at accelerating psychedelic research and fast-tracking FDA reviews for breakthrough mental health treatments. The community is actively debating the company's status as a late-stage clinical leader, with many highlighting its potential to benefit from the new regulatory landscape as it approaches major clinical milestones and potential commercialization.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Investors are closely watching the iShares MSCI Brazil ETF ($EWZ) as technical indicators and macro tailwinds, such as a weakening US dollar and potential emerging market capital inflows, spark renewed interest. The community remains divided, weighing the allure of high dividend yields and commodities leverage against concerns over political developments and regional economic stability.

AEVEX Corp. operates as a holding company. It operates through Tactical Systems and Global Solutions segments. The Tactical Systems segment focuses on design, development, and production of autonomous systems including unmanned aerial systems and unmanned surface vessels. The Global Solutions segment offers services and mission support to defense and intelligence customers. The company was founded in 2017 and is headquartered in Solana Beach, CA.

AEVEX Corp. - Ordinary Shares - Class A

AEVEX Corp. is trending following its recent NYSE debut as traders capitalize on its position within the high-demand defense and autonomous drone sector. The community is actively debating the stock's momentum potential, weighing strong government contract backing against high volatility and comparisons to other recent IPOs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine (NASDAQ:LPCN) Director Buys $81,200.00 in Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi bought 40,000 shares of the firm's stock in a transaction dated Tuesday, April 7th. The stock was purchased at an average cost of...

Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of Lipocine stock in a transaction that occurred on Monday, April 6th. The shares were bought at an average cost...

What's Going On With Lipocine Stock On Monday?

Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouraging subgroup data.read more...

Insider Buying: Lipocine (NASDAQ:LPCN) CEO Purchases 25,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel purchased 25,000 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The shares were acquired at an average cost of $2.02 per share, with a total value of $50,500.00. Following the completion of the...

<ul class="summary-bullets"><li>While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile, the company said.&nbsp;</li><li>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154.</li><li>The company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward.</li></ul>Shares of Lipocine Inc. (LPCN) fell 78% on Thursday after the company said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.While the trial failed its primary endpoint of significant reduction in depression severity, the drug was well tolerated and demonstrated a favorable safety profile enough to support outpatient administration without the need for healthcare provider monitoring, the company said. No treatment-related severe or serious adverse events were reported and no cases of excessive sedation or loss of consciousness were observed, it added.<h2 class="st-heading-2">What’s Next For Lipocine?</h2>Lipocine, however, said that it has identified signals in a post hoc analysis that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with postpartum depression based on the post hoc analysis results, the company said.While it waits for the FDA to get back, the company said it will preserve capital and engage with shareholders to evaluate all options available to the company going forward, including continued development of LPCN 1154, development of other product candidates, strategic transactions, partnerships, and other opportunities, it said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around LPCN rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user drew focus to the company’s remaining pipeline, which includes experimental drugs for the treatment of non-alcoholic steatohepatitis, for the management of symptoms associated with cirrhosis and another for the prevention of recurrent preterm birth.<stembedurl>https://www.stocktwits.com/Boknow/message/649308142</stembedurl>Another user expressed hopes for a minor recovery after the crash. &nbsp;<stembedurl>https://www.stocktwits.com/Ruttobillions/message/649292640</stembedurl><a href="https://stocktwits.com/symbol/LPCN">LPCN stock</a> has dropped 37% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sgml-stock-soars-on-100-m-bank-guarantee-retail-says-one-last-hurdle-is-behind/cZ7xCWQRI8Z">SGML Stock Soars On $100M Bank Guarantee, Retail Says 'One Last Hurdle' Is Behind</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lipocine is displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

LPCN Stock Crashes 78%— Here’s Why 

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.

Equity

Lipocine said that its experimental drug LPCN 1154 did not bring about a significant reduction in the severity of postpartum depression in a trial.


Lipocine Stock Tanks 78% After Phase 3 Oral Brexanolone Trial Failed To Meet Primary Endpoint

(RTTNews) - Shares of Lipocine Inc. (LPCN) are falling about 78 percent on Thursday morning trading following the announcement of topline results from its Phase 3 placebo-controlled trial, which failed to meet the primary endpoint. The trial evaluated LPCN 1154 or oral brexanolon...

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression

Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with...

Lipocine (NASDAQ:LPCN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Lipocine from a "sell" rating to a "hold" rating in a report on Sunday...

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire SALT LAKE CITY, March 10...

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

LPCN
Lipocine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LPCN News

LPCNLipocine Inc